These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20803482)

  • 21. Assessing a surrogate predictive value: a causal inference approach.
    Alonso A; Van der Elst W; Meyvisch P
    Stat Med; 2017 Mar; 36(7):1083-1098. PubMed ID: 27966231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On assessing surrogacy in a single trial setting using a semicompeting risks paradigm.
    Ghosh D
    Biometrics; 2009 Jun; 65(2):521-9. PubMed ID: 18759839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating futility of a binary clinical endpoint using early read-outs.
    Van Lancker K; Vandebosch A; Vansteelandt S; De Ridder F
    Stat Med; 2019 Dec; 38(28):5361-5375. PubMed ID: 31631357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the predictive value of a binary surrogate for a binary true endpoint based on the minimum probability of a prediction error.
    Meyvisch P; Alonso A; Van der Elst W; Molenberghs G
    Pharm Stat; 2019 May; 18(3):304-315. PubMed ID: 30575256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach.
    Alonso A; Geys H; Molenberghs G; Kenward MG; Vangeneugden T
    Biometrics; 2004 Dec; 60(4):845-53. PubMed ID: 15606404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed.
    Daniel RM; Tsiatis AA
    Lifetime Data Anal; 2013 Oct; 19(4):513-46. PubMed ID: 23722304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma.
    Medeiros FA
    Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO20-BIO26. PubMed ID: 28475699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prentice's approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints.
    Alonso A; Molenberghs G; Burzykowski T; Renard D; Geys H; Shkedy Z; Tibaldi F; Abrahantes JC; Buyse M
    Biometrics; 2004 Sep; 60(3):724-8. PubMed ID: 15339295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A group sequential Holm procedure with multiple primary endpoints.
    Ye Y; Li A; Liu L; Yao B
    Stat Med; 2013 Mar; 32(7):1112-24. PubMed ID: 23239078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The individual-level surrogate threshold effect in a causal-inference setting with normally distributed endpoints.
    Van der Elst W; Abad AA; Coppenolle H; Meyvisch P; Molenberghs G
    Pharm Stat; 2021 Nov; 20(6):1216-1231. PubMed ID: 34018666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the relationship between association and surrogacy when both the surrogate and true endpoint are binary outcomes.
    Meyvisch P; Alonso A; Van der Elst W; Molenberghs G
    Stat Med; 2020 Nov; 39(26):3867-3878. PubMed ID: 32875590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
    Methy N; Bedenne L; Bonnetain F
    BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling.
    Ghosh D; Taylor JM; Sargent DJ
    Biometrics; 2012 Mar; 68(1):226-32. PubMed ID: 21668903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in surrogate threshold effect estimates between original and simplified correlation-based validation approaches.
    Schürmann C; Sieben W
    Stat Med; 2016 Mar; 35(7):1049-62. PubMed ID: 26522510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A perfect correlate does not a surrogate make.
    Baker SG; Kramer BS
    BMC Med Res Methodol; 2003 Sep; 3():16. PubMed ID: 12962545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intermediate markers as surrogate endpoints in cancer research.
    Schatzkin A
    Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints.
    Alonso A; Van der Elst W; Molenberghs G; Buyse M; Burzykowski T
    Biometrics; 2015 Mar; 71(1):15-24. PubMed ID: 25274284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials.
    Rotolo F; Paoletti X; Michiels S
    Comput Methods Programs Biomed; 2018 Mar; 155():189-198. PubMed ID: 29512498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A closed-form estimator for meta-analysis and surrogate markers evaluation.
    Flórez AJ; Molenberghs G; Verbeke G; Abad AA
    J Biopharm Stat; 2019; 29(2):318-332. PubMed ID: 30365364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gatekeeping testing via adaptive alpha allocation.
    Li JD; Mehrotra DV
    Biom J; 2008 Oct; 50(5):704-15. PubMed ID: 18932133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.